Delving into the Latest Updates on Sodium Thiosulfate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Monosulfanemonosulfonic acid, Sodium Aurotiosulfate, Sodium Thiosulfate Hydrate

+ [12]

Target-

Mechanism

Sulfur atom donors

Therapeutic Areas

Otorhinolaryngologic DiseasesOther DiseasesNeoplasms+ [1]

Active Indication

OtotoxicityDisinfectantsPoisoning+ [2]

Inactive Indication

Calciphylaxis

Originator Organization

Nichi-Iko Pharmaceutical Co., Ltd.

Active Organization

Kenei Pharmaceutical Co Ltd.

Decibel Therapeutics, Inc.

Tianjin Jinyao Pharmaceutical Co., Ltd.

+ [4]

Inactive Organization

U.S. Army War College

Drug Highest PhaseApproved

First Approval Date

JP (11 May 1984),

Poisoning

RegulationOrphan Drug (EU), Fast Track (US), Breakthrough Therapy (US), Priority Review (CN)

Login to view timeline

Structure

Molecular FormulaH2O3S2

InChIKeyDHCDFWKWKRSZHF-UHFFFAOYSA-N

CAS Registry13686-28-7

View All Structures (2)

The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.

Start Date01 Dec 2024

Sponsor / Collaborator

University of Pittsburgh

[+1]

CTIS2023-510255-34-00 / Not yet recruitingIIT

A prospective, multi-centre, open-label, investigator-initiated randomised controlled study investigating calcinosis cutis in patients with systemic sclerosis undergoing treatment with sodium thiosulfate assessed by novel biomarkers and diagnostic imaging

Start Date22 May 2024

Sponsor / Collaborator

Århus Universitetshospital

TCTR20240520004 / Not yet recruitingPhase 3IIT

Efficacy of intratympanic sodium thiosulfate gel injection to preventisplatin-induced ototoxicity: a randomized controlled trial

Start Date20 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with Sodium Thiosulfate

Login to view more data

100 Translational Medicine associated with Sodium Thiosulfate

Login to view more data

100 Patents (Medical) associated with Sodium Thiosulfate

Login to view more data

1,309

Literatures (Medical) associated with Sodium Thiosulfate

01 Dec 2024·European Journal of Surgical Oncology

Acute kidney injury after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy - A systematic review

Review

Author: Solanki, Sohan Lal ; Bhatt, Aditi ; Kuberkar, Deepali V ; Gangakhedkar, Gauri ; Kuberkar, Deepali V. ; Salunke, Bindiya ; Ambulkar, Reshma

The use of nephrotoxic chemotherapeutic agents during hyperthermic intraperitoneal chemotherapy (HIPEC), carries the risk of postoperative acute kidney injury (AKI). The available evidence on this subject is sparse with variability in the reported incidence of AKI. In this systematic review, the aim was to analyse the incidence, risk factors, and preventive measures for AKI after cytoreductive surgery and HIPEC. A systematic literature search was conducted using the terms 'Acute kidney injury', 'Acute kidney failure', 'Acute renal failure', 'Acute renal impairment', 'HIPEC Surgery', 'Cytoreductive Surgery', 'Heated Chemotherapy' on PubMed, Scopus, clinical trial.gov, POPLINE and Google Scholar. Randomized controlled trials, cohort studies and observational studies published from January 2000-December 2020 were included. The systematic review was registered in the International Prospective Register of Systematic Reviews (PROSPERO) (CRD42021247781). Data from 16 articles, which included 1622 patients, was included. The incidence AKI by any definition, was 23.36 %. The highest incidence of AKI (45.45 %) was reported after paclitaxel-HIPEC. The incidence of AKI after cisplatin-HIPEC was 34.7 %. Cisplatin HIPEC was the most common factor associated with AKI in 7/16 studies followed by pre-existing comorbidities and low intraoperative diuresis in 4 and 3 studies respectively. The perioperative use of sodium thiosulfate and amifostine led to a significant reduction in the incidence of AKI. The reported incidence of AKI after CRS-HIPEC is high. Identifying preoperative risk factors, optimising comorbidities, maintaining perioperative haemodynamic stability, perioperative use of sodium thiosulfate, maintaining adequate diuresis could reduce the incidence of AKI.

01 Dec 2024·Marine Pollution Bulletin

Detoxification effect of sodium thiosulfate on cadmium poisoning in Litopenaeus vannamei and the mechanisms of intestinal flora regulation

Article

Author: Wang, Xuejie ; Hou, Danqing ; Gao, Shan ; Sun, Chengbo ; Li, Ting ; Dong, Jiaxin ; Yu, Jianbo

Cadmium (Cd) is currently one of the heavy metals with the highest environmental toxicity impact. Sodium thiosulfate (Na₂S₂O₃) is a commonly used heavy metal detoxification drug in clinical practice, however, it has not been used for Cd detoxification of Litopenaeus vannamei. The present study used exposure of L. vannamei to 150 μg/L of Cd while mitigating in the addition of 75 μg/L of Na₂S₂O₃ for 28 days. The goal was to study the detoxifying effect of Na₂S₂O₃ on L. vannamei poisoning and its role in intestinal flora. The results showed that the growth of Cd group was inhibited, and the growth rate and weight gain of Cd + ST group were greater than that of Cd group. The function and structure of L. vannamei intestinal microorganisms were significantly changed under Cd stress. This work reveals that Na₂S₂O₃ can mitigate the damage caused by this concentration to L. vannamei to a certain extent.

01 Dec 2024·Bioresource Technology

Comparative analysis of sulfur-driven autotrophic denitrification for pilot-scale application: Pollutant removal performance and metagenomic function

Article

Author: Jiang, Yu ; Du, Jing ; Cui, Peng ; Zou, Lei ; Ma, Min ; Li, Chaoyu ; Wan, Nianhong

Two parallel pilot-scale reactors were operated to investigate pollutant removal performance and metabolic pathways in elemental sulfur-driven autotrophic denitrification (SDAD) process under low temperature and after addition of external electron donors. The results showed that low temperature slightly inhibited SDAD (average total nitrogen removal of ∼4.7 mg L^-1) while supplement of sodium thiosulfate (stage 2) and sodium acetate (stage 3) enhanced denitrification and secretion of extracellular polymeric substances (EPS), leading to the average removal rate of 0.75 and 1.01 kg N m^-3 d^-1, respectively with over twice higher total EPS. Correspondingly, nitrogen and sulfur related microbial metabolisms especially nitrite reductase and nitric oxide reductase encoding were promoted by genera including Thermomonas and Thiobacillus. The variations revealed that extra sodium acetate improved denitrification and enriched more SDAD-related microorganisms compared with sodium thiosulfate, which potentially catalyzed the refinement of practical strategies for optimizing denitrification in low carbon to nitrogen ratio wastewater treatment.

68

News (Medical) associated with Sodium Thiosulfate

13 Nov 2024

·www.globenewswire.com

Fennec Pharmaceuticals to Participate in Upcoming Investor Conference

RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference. The Company's management will be available for one-on-one meetings throughout the event. Conference Details: Event: 15th Annual Craig-Hallum Alpha Select ConferenceDate: November 19, 2024Location: Sheraton New York Times Square Hotel, New York City About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate & Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Orphan DrugDrug Approval

31 Oct 2024

·www.globenewswire.com

Fennec Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024

RESEARCH TRIANGLE PARK, N.C., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its third quarter 2024 financial results before the opening of the U.S. financial markets on Thursday, November 7, 2024. Management will host a conference call and webcast that day to discuss the Company’s financial and business results. Conference Call & Webcast Detail: Date:Thursday, November 7, 2024Time:8:30 a.m. Eastern TimeLink:https://edge.media-server.com/mmc/p/e6my278s To access the conference call, please register using https://edge.media-server.com/mmc/p/e6my278s. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.fennecpharma.com and proceed to the News & Events/Event Calendar page under the Investors & Media heading. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. A webcast replay of the conference call will also be archived on www.fennecpharma.com for thirty days. About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate and Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Drug ApprovalFinancial StatementOrphan Drug

05 Sep 2024

·www.globenewswire.com

Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences. Conference Details: Event: H.C. Wainwright Global Investment ConferenceDate: September 11, 2024Time: Company Presentation at 12:00 p.m. – 12:30 p.m. ETLocation: New York City, Lotte NY Palace Hotel, Holmes 1, 4th Floor Event: Cantor Fitzgerald Global Healthcare ConferenceDate: September 19, 2024Time: Fireside Chat at 8:35 a.m. – 9:05 a.m. ETLocation: New York City, InterContinental Barclay Hotel, Track 3, Grand Ballroom 1 For additional information, please visit the investor relations section of the Company’s website at:https://investors.fennecpharma.com/events-and-presentations/events. About Fennec PharmaceuticalsFennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK® to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission approval in June 2023 and U.K. approval in October 2023 under the brand name PEDMARQSI. PEDMARK has received Orphan Drug Exclusivity in the U.S. and PEDMARQSI has received Pediatric Use Marketing Authorization in Europe, which includes eight years plus two years of data and market protection. For more information, please visit www.fennecpharma.com. For further information, please contact: Investors:Robert AndradeChief Financial OfficerFennec Pharmaceuticals Inc.+1 919-246-5299 Corporate & Media:Lindsay Rocco Elixir Health Public Relations+1 862-596-1304lrocco@elixirhealthpr.com

Drug ApprovalOrphan Drug

100 Deals associated with Sodium Thiosulfate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D01091	Sodium Thiosulfate	V03AB06	DB09499

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Ototoxicity	US	Fennec Pharmaceuticals, Inc.	20 Sep 2022
Disinfectants	JP	Kenei Pharmaceutical Co Ltd.	12 Nov 2013
Poisoning	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	-

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Phase 1	US	Decibel Therapeutics, Inc.	21 Feb 2020
Neoplasms	Phase 1	AU	Decibel Therapeutics, Inc.	21 Feb 2020
Ototoxicity	Phase 1	US	Decibel Therapeutics, Inc.	21 Feb 2020
Ototoxicity	Phase 1	AU	Decibel Therapeutics, Inc.	21 Feb 2020
Hearing Loss	Preclinical	US	Fennec Pharmaceuticals, Inc.	31 Jan 2023
Calciphylaxis	Discovery	CA	Hope Pharmaceuticals, Inc.	24 May 2017
Calciphylaxis	Discovery	US	Hope Pharmaceuticals, Inc.	24 May 2017
Calciphylaxis	Discovery	GB	Hope Pharmaceuticals, Inc.	24 May 2017

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04541355 (CTgov)	Phase 2	Squamous cell carcinoma of the oral cavity \| Ototoxicity \| Nasopharyngeal Carcinoma \| Laryngeal Neoplasms \| HPV positive oropharyngeal squamous cell carcinoma \| Locally Advanced Head and Neck Squamous Cell Carcinoma	16	Hearing Handicap Inventory for Adults - Screening+Sodium Thiosulfate+Cisplatin	eihsalasgh(sqceniesue) = ewunvrqbbb mueooyrgrs (ckzjnkyqnz, zrgdjfuatu - lzcrqzraii) View more	-	28 Jun 2024
ISN WCN2024	Not Applicable	Calciphylaxis	-	Sodium Thiosulphate	lowmlfganz(lwialxnzfe) = vzumgmnymc lxtsxwgnsh (yztxrhvldv )	-	01 Apr 2024
NCT03267277 (CTgov)	Phase 2/3	Dermatomyositis \| Calcinosis	15	Sodium Thiosulfate	ouxvtudzgf(qklfevazho) = fyrigledke xodaopqrgh (qfayuychgv, ruapatxrrf - hdgnbkidhs) View more	-	26 Feb 2024
WCD2023	Not Applicable	Calciphylaxis Adjuvant	-	Intralesional sodium thiosulfate	oxleldelqy(ypahxyyrzz) = hqlavdqbcg gkitwgzmfu (qxnxvhzqhn ) View more	-	07 Jul 2023
EMA Manual	Not Applicable	Ototoxicity	104	cisplatin (with different types of cancer)	damllewxya(sshfnoxvqt) = The risk of having hearing loss was statistically significantly lower in the CIS+STS arm compared with the CIS Alone arm, corresponding to a clinically meaningful 48% lower risk after STS treatment. wyrrtggjpw (nzdgpnaocd ) View more	Positive	02 Jun 2023
				sodium thiosulfate+cisplatin (with different types of cancer)
EMA Manual	Not Applicable	Ototoxicity	109	cisplatin (with hepatoblastoma)	cwcgrqiyna(owpzzclmmq) = jgiprsbnfq igfmbbcohz (zbjpaxopeb ) View more	Positive	02 Jun 2023
				sodium thiosulfate+cisplatin (with hepatoblastoma)	cwcgrqiyna(owpzzclmmq) = dlzyjbuwza igfmbbcohz (zbjpaxopeb ) View more
NCT00293475 (ASCO2023) Manual	Phase 1/2	Primary Central Nervous System Lymphoma First line	17	rituximab+Carboplatin+Mannitol+Methotrexate+Sodium Thiosulfate	(oshcxyowca) = xbhmxwolul wmbnhcfjgg (elicgnvnqk ) View more	Positive	31 May 2023
NCT04262336 (ASCO2023) Manual	Phase 1	Ototoxicity	19	DB-020	(qdaqwjldcx) = Ear pain (15/19 subjects, 78.9%) and tinnitus (8/19 subjects, 42.1%) were common. Ear pain was more common in DB-020 treated ears, and tinnitus was more common in placebo treated ears. jleodcwzxx (afditmpasi ) View more	Positive	26 May 2023
				Placebo
NCT04262336 (Corporate Publications) Manual	Phase 1	Hearing Loss	19	DB-020	mhrtvbfbvw(bgzctmqhpz) = xwrtutugty gpklvkjzoh (rahasvrvqq )	Positive	28 Jun 2022
				Placebo	mhrtvbfbvw(bgzctmqhpz) = wmtoymgrkv gpklvkjzoh (rahasvrvqq )
NCT03639779 (CTgov)	Phase 4	Calcinosis cutis	5	Sodium Thiosulfate (Sodium Thiosulfate)	dvtvqrcrae(eagqoesmff) = iwwurpwnwj mdxdsmzlwm (pmchcqfbgc, npmyljedgf - bzwzvidojv) View more	-	01 Jul 2021
				Saline Solution (Saline Solution)	dvtvqrcrae(eagqoesmff) = cdqqpwrklb mdxdsmzlwm (pmchcqfbgc, umjkcavkfh - hmcmjyoljo) View more